AUROPHARMA1,666.00

Aurobindo Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLAFORTISLUPINALKEMLAURUSLABSMANKINDMcap ₹96,761 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)332.22358.44426.90426.90
Receivable Days (DSO)60.6266.1176.9576.95
Payable Days (DPO)150.87142.40197.19190.54
Cash Conversion Cycle (days)241.97282.15306.66313.31
Working Capital Turnover2.512.542.292.38
Asset Turnover0.640.640.580.58
Cash Conversion (CFO/Net Income)0.771.131.581.58
CFO/EBITDA0.420.600.810.81
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.